Proprietary Brain-Responsive Technology: The RNS System is the only FDA-approved brain-responsive neurostimulation device that directly monitors and responds to a patient's unique brain activity, offering a truly personalized therapy for drug-resistant focal epilepsy.

Strong Intellectual Property Portfolio: Extensive patents protect the core RNS technology, including its detection algorithms, stimulation paradigms, and hardware, creating a significant barrier for potential competitors.

Established Clinical Efficacy and Long-Term Data: Decades of clinical research and real-world data demonstrate sustained seizure reduction and improved quality of life for patients over many years, building trust with physicians and patients.